Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic Cell Vaccine in Chronic Myeloid Leukemia
NCT02543749Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jul 2014
- Primary completion
- Jul 2022
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous dendritic cell vaccine in chronic myeloid leukemia (CML), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Dendritic Cell Toxicity Parameters at 30 weeks. Started Jul 2014; status: terminated.
02
Drugs
autologous dendritic cell vaccine
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02543749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02543749.